Hims & Hers plans to sell legally compoundable peptides by end-2026 and is testing BPC-157. What its pharmacy infrastructure, the FDA 503A vote and analyst caution mean for the peptide market.
Written by the Peptide Labs Research Team
Hims & Hers has been careful about what it is committing to. On the company's Q2 2026 earnings call, chief executive Andrew Dudum said Hims is "currently developing a best-in-class peptides experience, including U.S. manufactured products, clinical-led guidance, and ongoing blood testing." Chief financial officer Yemi Okupe put it in plainer commercial terms: "Scaling new specialties is one of our core levers."
The near-term catalogue is narrow by design. Reuters reported the initial offering will cover sermorelin, glutathione and NAD+ — compounds that US compounding pharmacies may already legally prepare against an individual prescription. Sermorelin is the cleanest case: it was approved as Geref in 1997, withdrawn from the market in 2008 for commercial reasons, and confirmed by the FDA in a 2013 Federal Register determination as not having been withdrawn for reasons of safety or effectiveness. That determination is what keeps it compoundable today.
What Hims is not doing is equally instructive. It is not launching BPC-157, and it is not describing any of these compounds as approved treatments.
| Category | What it means | Examples in this story |
|---|---|---|
| FDA-approved | Reviewed and authorised for a specific indication | GLP-1 medicines such as semaglutide |
| Compounded | Prepared by a licensed pharmacy for an individual prescription; not FDA-approved as a product | Sermorelin, glutathione, NAD+ |
| Investigational / unapproved | No approval; limited or no human safety and efficacy data | BPC-157, TB-500, MOTS-c, Epitalon, Semax, KPV |
A compounded preparation is not an approved drug that happens to be made locally. It is a preparation that has never been through the approval process at all, permitted under a specific statutory carve-out. Most consumer-facing peptide marketing collapses these three columns into one, and that is where most of the regulatory trouble originates.
The plan is credible mainly because the plumbing already exists. Hims closed Q2 2026 with US$753.2 million in revenue, up 38% year on year, and nearly 2.9 million subscribers, raising full-year guidance to US$3.1–3.3 billion while absorbing an US$86.3 million net loss on expansion and acquisition costs.
Three assets matter specifically for peptides:
Prescriber, pharmacy, manufacturer, lab, logistics and subscription billing under one roof. That stack, rather than the product list, is the actual news.
BPC-157 is the most-watched peptide in the category and the most legally fraught. The FDA placed it in Category 2 in September 2023 — substances that "may present significant safety risks" — citing immunogenicity, peptide-related impurities and an absence of human safety data. In April 2026 the agency removed it from Category 2 after nominations were withdrawn, but did not move it to Category 1.
On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8–6 to recommend adding BPC-157 (free base and acetate) to the 503A Bulks List, and also backed KPV, TB-500, MOTS-c, Epitalon and Semax while rejecting emideltide. Hims shares rose around 10% that day.
The counterweight is stark. BPC-157 has been studied in roughly 30 humans — orders of magnitude less exposure than the GLP-1 medicines Hims already dispenses. Advisory committee votes do not bind the FDA, and formal addition to the Bulks List requires rulemaking that analysts expect to take about a year, with sign-off at HHS level.
Running stability and validation work now while withholding commercial launch is a rational straddle: build readiness, avoid selling an unapproved substance ahead of a rule.
Consumer peptide demand grew almost entirely outside the regulated system — through research-chemical vendors, grey-market importers and wellness clinics. Three things drove it: GLP-1 medicines normalised self-injection for millions of people; longevity marketing ran well ahead of the evidence; and no trusted, accountable supplier existed. That combination produced a market with genuine willingness to pay and almost no legitimate channel. For a company whose core competency is converting unmet demand into a subscription, the gap is the opportunity.
Standalone peptide sellers compete on price and speed. A vertically integrated telehealth operator competes on things a small vendor structurally cannot match: documented US manufacturing and chain of custody; licensed prescribers making an individual determination; third-party potency and sterility testing; longitudinal bloodwork; adverse-event tracking; and the ability to spread legal and compliance overhead across millions of subscribers.
If the FDA finalises a Bulks List including several of these peptides, the result is a compliance moat. Every requirement — valid prescription, qualified bulk substance, USP-compliant preparation — is a fixed cost that rewards scale. Many grey-market sellers currently shipping research-use-only vials cannot cross that threshold at all.
The risks are not hypothetical:
Investors who spoke to Reuters were consistent: peptides will not drive 2026 growth. Paul Cerro of Cedar Grove Capital put it bluntly — "There's no 'release the floodgates' demand like there is for other peptides." Morningstar's Keonhee Kim noted that NAD+ demand is hard to value precisely because so much of it already clears through the grey market at grey-market prices. Raul Shah of DocShah Financial was more constructive on the long arc, projecting over US$1 billion in peptide revenue within five to ten years while arguing Hims has no need to rush.
Against a US$3.1–3.3 billion revenue base, a total addressable market of US$2.2–3.3 billion that Hims will share is a category, not an inflection point.
Expect four shifts. Consolidation: unlicensed sellers lose the legal ambiguity they depend on once a compliant channel exists. Price compression, with margin migrating to whoever owns manufacturing. A visible evidence gap: at-scale bloodwork and adverse-event reporting will, for the first time, generate real-world data on compounds studied in dozens of people — and that data may not flatter every peptide. Regulatory tightening as a consequence of legitimisation, not despite it, because volume attracts inspection.
The signal in the Hims announcement is not that peptides have been validated. It is that the category is being pulled inside a regulated, capitalised, data-generating system — and the answers, favourable or not, will arrive faster than the marketing did.
Nothing in the 503A process changes Australian regulatory status. The Bulks List is a US compounding mechanism with no equivalent effect here, and compounds such as BPC-157 and TB-500 remain unapproved therapeutic goods under the Therapeutic Goods Act 1989. Australian supply of these compounds continues to sit in the research-use-only category, and a favourable US rulemaking would not alter that.
Is BPC-157 legal to buy in the US?
BPC-157 is not FDA-approved. As of August 2026 it is not on the 503A Bulks List; an advisory committee has recommended adding it, but rulemaking is unfinished. Material sold for research use only is not authorised for human use.
Are sermorelin, glutathione and NAD+ FDA-approved?
Not as marketed products for longevity or wellness indications. They are dispensed as compounded preparations against a valid prescription. Sermorelin's compoundability derives from Geref's prior approval and the FDA's 2013 determination that it was withdrawn for non-safety reasons.
When will Hims & Hers actually sell peptides?
The company has signalled an offering of already-permitted peptides before the end of 2026, and says it will wait for final FDA rulemaking on peptides still under review.
Does the advisory committee vote mean BPC-157 is safe?
No. The vote concerns eligibility for compounding, not approval, and is non-binding. The FDA previously cited immunogenicity, impurity and missing human safety data; human exposure remains around 30 subjects.
Does any of this change the rules in Australia?
No. US compounding decisions have no direct effect on TGA regulation or on the research-use-only status of these compounds in Australia.
Disclaimer: This article is business and regulatory analysis provided for educational purposes. It is not medical, legal or investment advice, and it does not recommend or endorse the use of any compound. Compounds discussed here that are supplied by Peptide Labs are sold strictly for in-vitro laboratory research and are not intended for human consumption.
Peptides are short chains of amino acids. This guide covers what they are, how they differ from proteins, the main classes studied in research, and how quality is verified.
Research GuidesPeptides, polypeptides and proteins are all amino acid chains. Here is how length, folding and function separate them, and what a peptide bond actually is.
99%+ HPLC purity · COA verified every batch · Next-day dispatch to Melbourne
Shop All Peptides